Koppel was born in New York City, the daughter of Ted Koppel, a television journalist, and Grace Anne Dorney Koppel, an attorney and spokesperson for Chronic obstructive pulmonary disease (COPD).
Phosphodiesterase (PDE) inhibitors, such as theophylline, have been used to treat Chronic Obstructive Pulmonary Disease (COPD) for centuries; however, the clinical benefits of these agents have never been shown to out-weigh the risks of their numerous adverse effects.
The main strand of the Health Forecasting project is forecasting the risk of exacerbation for people with chronic obstructive pulmonary disease (COPD).
Further changes to the QOF for 2008 included the addition of new indicators for COPD and smoking cessation.
Parkinson's disease | Alzheimer's disease | Centers for Disease Control and Prevention | Huntington's disease | Centers for Disease Control | Bright's disease | Dutch elm disease | disease | Crohn's disease | Chagas disease | sexually transmitted disease | Plague (disease) | Chronic obstructive pulmonary disease | Sexually transmitted disease | Lyme disease | Gaucher's disease | cardiovascular disease | Asbestos Disease Awareness Organization | Alzheimer's Disease | Paget's disease of bone | Motor Neurone Disease Association | Graves' disease | End stage renal disease | chronic obstructive pulmonary disease | Chronic kidney disease | chronic kidney disease | Chronic fatigue syndrome | Cardiovascular disease | Batten disease | Tay-Sachs disease |
Since January 2006, Dorney has also been active as a national spokeswoman and patient advocate for the National Heart, Lung, and Blood Institute of the National Institutes of Health in the hopes of raising awareness of Chronic Obstructive Pulmonary Disease (COPD) which affects some 24 million Americans, 12 million of whom are undiagnosed and untreated.
Pulsus paradoxus is a sign that is indicative of several conditions, including cardiac tamponade, pericarditis, chronic sleep apnea, croup, and obstructive lung disease (e.g. asthma, COPD).
Three thousand and thirty people with one of three conditions (Diabetes, Chronic Heart Failure and COPD) were included in the telehealth trial.
Vilanterol (USAN), or triphenylacetic acid, is a long-acting beta-2 agonist drug, which in May 2013 was approved in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).